BioSpace News Archive

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 22, 2020.

This morning, the Switzerland-based company said its SPIRIT-2 study met its co-primary efficacy endpoints and six key secondary endpoints for endometriosis treatment.

The goal is to support the discovery and development of next-generation drug and engineered cell therapies, specifically with a focus on natural killer (NK) cells.

A new life sciences facility dubbed The Labs has opened in Chicago providing necessary wet lab space for companies looking to expand their physical presence in the Windy City and cement the city’s reputation as a hub for cutting edge biomedical innovation.

The FDA recently approved the combination of Imbruvica-Rituximab for treating chronic lymphocytic leukemia. Here’s everything you need to know.

The interest in psychedelic medicine – particularly psilocybin, a pro-drug derived from some 200 varieties of the so-called magic mushrooms – stems from multiple factors.

Ken Pienta, acting chief medical officer of Cue Biopharma, said the researchers believe that CUE-101 may lead to enhanced anti-tumor activity in combination with Merck’s powerhouse checkpoint inhibitor.

Researchers at Switzerland-based Empa, ETH Zurich and Zurich University Hospital have developed a sensor that has the potential to identify SARS-CoV-2, the novel coronavirus that causes COVID-19, in the air.

Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology and currently focused on sexual health and pain, is pleased to announce that it has now filed for a further pre-submission meeting with the US FDA following receipt of the complete and signed clinical study report for its Phase 3 Study.

After leading a flurry of collaborations with multiple companies to hasten the development of vaccine candidates and treatments for COVID-19, Rick Bright, the director of BARDA, has abruptly departed his post for another position in the government.